Phase 3 Clinical Trials With Primary Completion Dates in May 2026
This is a list of Phase 3 trials with primary completion dates in May 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | 2026-05-01 | Phase 3 | NCT06741228 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) |
| GRFS | Grifols, S.A. | 2026-05-01 | Phase 3 | NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma |
| INCPF | InnoCare Pharma Limited | 2026-05-01 | Phase 3 | NCT06842199 | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
| NMRA | Neumora Therapeutics, Inc. | 2026-05-01 | Phase 3 | NCT06058013 | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| NMRA | Neumora Therapeutics, Inc. | 2026-05-01 | Phase 3 | NCT06058039 | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| OPHLY | Ono Pharmaceutical Co., Ltd. | 2026-05-01 | Phase 3 | NCT05144854 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |